Stockreport

Sumitomo Pharma America Announces that its Investigational Therapy DSP-3077 Has Received FDA Orphan Drug Designation for the Treatment of Retinitis Pigmentosa [Yahoo! Finance]

SUMITOMO CHEM UNSP/ADR  (SOMMY) 
NASDAQ:AMEX Investor Relations: sumitomo-chem.co.jp/english/ir
PDF – Retinitis pigmentosa (RP) is a group of genetic eye disorders characterized by the progressive degeneration of photoreceptor cells in the retina, leading to vision lo [Read more]